Walleye Capital LLC C4 Therapeutics, Inc. Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.05 - $8.1 $49,928 - $99,856	-12,328 Reduced 23.57%	39,976 $184,000
Q1 2024 May 15, 2024	BUY	$5.3 - $11.0 $277,211 - $575,344	52,304 New	52,304 $427,000
Q1 2023 May 15, 2023	SELL	$3.1 - $9.02 $40,129 - $116,763	-12,945 Reduced 30.29%	29,792 $93,000
Q4 2022 Feb 14, 2023	SELL	$5.42 - $10.24 $367,871 - $695,019	-67,873 Reduced 61.36%	42,737 $252,000
Q3 2022 Nov 14, 2022	SELL	$8.03 - $12.77 $1.64 Million - $2.6 Million	-203,656 Reduced 64.8%	110,610 $970,000
Q2 2022 Aug 08, 2022	BUY	$5.06 - $26.46 $1.59 Million - $8.32 Million	314,266 New	314,266 $2.37 Million
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $1.63 Million - $2.72 Million	-81,720 Closed	0 $0
Q4 2021 Mar 03, 2022	BUY	$29.39 - $46.86 $2.4 Million - $3.83 Million	81,720 New	81,720 $2.63 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $196M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.